Cargando…

Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control

BACKGROUND: High bronchodilator reversibility in adult asthma is associated with distinct clinical characteristics. In this study, we aim to make a comparison with T-helper 2 (Th2)-related biomarkers, lung function and asthma control between asthmatic patients with high airway reversibility (HR) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jianghong, Ma, Libing, Wang, Jiying, Xu, Qing, Chen, Meixi, Jiang, Ming, Luo, Miao, Wu, Jingjie, She, Weiwei, Chu, Shuyuan, Mo, Biwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307254/
https://www.ncbi.nlm.nih.gov/pubmed/30603020
http://dx.doi.org/10.1186/s13223-018-0315-0
_version_ 1783382965539045376
author Wei, Jianghong
Ma, Libing
Wang, Jiying
Xu, Qing
Chen, Meixi
Jiang, Ming
Luo, Miao
Wu, Jingjie
She, Weiwei
Chu, Shuyuan
Mo, Biwen
author_facet Wei, Jianghong
Ma, Libing
Wang, Jiying
Xu, Qing
Chen, Meixi
Jiang, Ming
Luo, Miao
Wu, Jingjie
She, Weiwei
Chu, Shuyuan
Mo, Biwen
author_sort Wei, Jianghong
collection PubMed
description BACKGROUND: High bronchodilator reversibility in adult asthma is associated with distinct clinical characteristics. In this study, we aim to make a comparison with T-helper 2 (Th2)-related biomarkers, lung function and asthma control between asthmatic patients with high airway reversibility (HR) and low airway reversibility (LR). METHODS: Patients with asthma diagnosed by pulmonologist according to Global Initiative for Asthma guidelines were recruited from the outpatient department of our hospital from August 2014 to July 2017. Patients were divided into HR and LR subgroups based on their response to bronchodilators of lung function (HR = Δforced expiratory volume in one second (FEV1) postbronchodilator ≥ 20%). Blood eosinophil count and serum IgE level, which are biomarkers of T-helper (Th)-2 phenotypes, were detected for patients. Asthma Control Test (ACT) was used to assess asthma control after the first-month initial treatment. RESULTS: A total of 265 patients with asthma were followed 1 month after initial treatment. HR group shows a higher level of Th2-high biomarkers (blood eosinophil count (10^9/L): 0.49 ± 0.28 vs 0.36 ± 0.19, P < 0.01; IgE (ng/ml): 1306 ± 842 vs 413 ± 261, P < 0.01), lower baseline lung function (FEV1%pred: 51.91 ± 19.34% vs 60.42 ± 19.22%, P < 0.01; forced expiratory flow (FEF)25–75: 0.76 ± 0.37 vs 1.00 ± 0.67, P < 0.01; FEF25–75%pred: 21.15 ± 10.09% vs 29.06 ± 16.50%, P < 0.01), and better asthma control (ACT score: 22 ± 4 vs 20 ± 4, P = 0.01) than LR group. HR was associated with a decreased risk of uncontrolled asthma after the first-month initial treatment (adjusted OR: 0.12 [95% confidence intervals: 0.03–0.50]). CONCLUSIONS: HR is a physiologic indicator of lower lung function and severer small airway obstruction, and is more related with an increased level of Th2-biomarkers than LR. Moreover, HR may indicate controlled asthma after the first-month initial treatment. This finding may contribute to identification of asthma endotype.
format Online
Article
Text
id pubmed-6307254
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63072542019-01-02 Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control Wei, Jianghong Ma, Libing Wang, Jiying Xu, Qing Chen, Meixi Jiang, Ming Luo, Miao Wu, Jingjie She, Weiwei Chu, Shuyuan Mo, Biwen Allergy Asthma Clin Immunol Research BACKGROUND: High bronchodilator reversibility in adult asthma is associated with distinct clinical characteristics. In this study, we aim to make a comparison with T-helper 2 (Th2)-related biomarkers, lung function and asthma control between asthmatic patients with high airway reversibility (HR) and low airway reversibility (LR). METHODS: Patients with asthma diagnosed by pulmonologist according to Global Initiative for Asthma guidelines were recruited from the outpatient department of our hospital from August 2014 to July 2017. Patients were divided into HR and LR subgroups based on their response to bronchodilators of lung function (HR = Δforced expiratory volume in one second (FEV1) postbronchodilator ≥ 20%). Blood eosinophil count and serum IgE level, which are biomarkers of T-helper (Th)-2 phenotypes, were detected for patients. Asthma Control Test (ACT) was used to assess asthma control after the first-month initial treatment. RESULTS: A total of 265 patients with asthma were followed 1 month after initial treatment. HR group shows a higher level of Th2-high biomarkers (blood eosinophil count (10^9/L): 0.49 ± 0.28 vs 0.36 ± 0.19, P < 0.01; IgE (ng/ml): 1306 ± 842 vs 413 ± 261, P < 0.01), lower baseline lung function (FEV1%pred: 51.91 ± 19.34% vs 60.42 ± 19.22%, P < 0.01; forced expiratory flow (FEF)25–75: 0.76 ± 0.37 vs 1.00 ± 0.67, P < 0.01; FEF25–75%pred: 21.15 ± 10.09% vs 29.06 ± 16.50%, P < 0.01), and better asthma control (ACT score: 22 ± 4 vs 20 ± 4, P = 0.01) than LR group. HR was associated with a decreased risk of uncontrolled asthma after the first-month initial treatment (adjusted OR: 0.12 [95% confidence intervals: 0.03–0.50]). CONCLUSIONS: HR is a physiologic indicator of lower lung function and severer small airway obstruction, and is more related with an increased level of Th2-biomarkers than LR. Moreover, HR may indicate controlled asthma after the first-month initial treatment. This finding may contribute to identification of asthma endotype. BioMed Central 2018-12-27 /pmc/articles/PMC6307254/ /pubmed/30603020 http://dx.doi.org/10.1186/s13223-018-0315-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wei, Jianghong
Ma, Libing
Wang, Jiying
Xu, Qing
Chen, Meixi
Jiang, Ming
Luo, Miao
Wu, Jingjie
She, Weiwei
Chu, Shuyuan
Mo, Biwen
Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control
title Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control
title_full Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control
title_fullStr Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control
title_full_unstemmed Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control
title_short Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control
title_sort airway reversibility in asthma and phenotypes of th2-biomarkers, lung function and disease control
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307254/
https://www.ncbi.nlm.nih.gov/pubmed/30603020
http://dx.doi.org/10.1186/s13223-018-0315-0
work_keys_str_mv AT weijianghong airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol
AT malibing airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol
AT wangjiying airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol
AT xuqing airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol
AT chenmeixi airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol
AT jiangming airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol
AT luomiao airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol
AT wujingjie airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol
AT sheweiwei airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol
AT chushuyuan airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol
AT mobiwen airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol